Spinogenix has reached a major milestone in its mission to transform neuropsychiatric care. Following FDA clearance of an IND application, enrollment is now open at a U.S. site for a Phase 2 clinical trial of SPG302—the first synaptic regenerative therapy being developed for schizophrenia.

In a recent interview, Christoph U. Correll, MD, shared why this new regenerative approach could be a turning point. “Schizophrenia is one of the most severe mental disorders, occurring in about 0.5% to 1.0% of the population,” he explained. “Most current treatments target dopamine and primarily address positive symptoms, leaving cognitive and negative symptoms largely untreated.”

SPG302 is designed to fill that gap. This once-daily oral medicine aims to restore glutamatergic synapses, with the potential to improve outcomes across all symptom domains.

“There is currently no other treatment targeting regeneration,” said Dr. Correll. “If successful, this could dramatically expand the treatment arsenal for schizophrenia.”

Beyond schizophrenia, SPG302 may open the door to regenerative strategies for other serious neurological conditions, including Alzheimer’s disease and ALS.

With enrollment now underway in the United States, SPG302 represents a new and promising direction in the treatment of schizophrenia—one focused on repairing the underlying synaptic loss that drives the disease.

To hear more from Dr. Correll about the promise of SPG302 and what makes this approach so unique, watch the full video interview | https://www.psychiatrictimes.com/view/spg302-a-synaptic-regenerative-treatment-option-for-schizophrenia.